Cizzle Biotechnology Holdings PLC
CIZ
Company Profile
Business description
Cizzle Biotechnology Holdings PLC is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is correlated with early stage lung cancer.
Contact
C/o SGH Secretaries Limited
60 Gracechurch Street
6th Floor
LondonEC3V 0HR
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,133.10 | 6.20 | 0.08% |
| CAC 40 | 7,804.63 | 71.73 | -0.91% |
| DAX 40 | 22,189.46 | 350.52 | -1.56% |
| Dow JONES (US) | 41,989.96 | 11.80 | -0.03% |
| FTSE 100 | 8,566.35 | 68.45 | -0.79% |
| HKSE | 23,202.53 | 4.31 | -0.02% |
| NASDAQ | 17,449.89 | 150.60 | 0.87% |
| Nikkei 225 | 35,725.87 | 101.39 | 0.28% |
| NZX 50 Index | 12,320.19 | 7.59 | 0.06% |
| S&P 500 | 5,633.07 | 21.22 | 0.38% |
| S&P/ASX 200 | 7,934.50 | 9.30 | 0.12% |
| SSE Composite Index | 3,350.13 | 1.69 | 0.05% |